All In Biotech

Drug Trial Radar · NCT05630768

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

A Multicenter, Open-label, Single-arm Clinical Trial to Evaluate the Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Last checked: Nov 20, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

149

Actual

Start

Jan 3, 2023

Primary completion

Jul 23, 2025

Study completion Jul 23, 2025

Sponsor

Lead sponsor
Dong-A ST Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • Risedronate Sodium 35 MG [Actonel]Drug

    Risendronate Sodium Tab. 35mg, orally, once weekly

  • Calcium Vitamin D combinationDrug

    orally, once daily for concomitant drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in lumbar spine bone mineral density (LS BMD) at 1 year (%)Time frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital

    Seoul, Seodaemun-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.